Results 41 to 50 of about 1,470 (198)

Cost-effectiveness of eculizumab and efgartigimod for the treatment of anti-acetylcholine receptor antibody-positive generalized myasthenia gravis. [PDF]

open access: yes
BACKGROUND: Eculizumab and efgartigimod were approved to treat anti-acetylcholine receptor antibody-positive generalized myasthenia gravis (anti-AChR Ab-positive gMG).
Agboola, Foluso   +7 more
core   +1 more source

Efgartigimod combined with steroids as a fast-acting therapy for anti-SRP immune-mediated necrotizing myopathy

open access: yesFrontiers in Neurology
BackgroundImmune-mediated necrotizing myopathy (IMNM) is a rare autoimmune disease. Efgartigimod is a human IgG antibody Fc fragment, can enhance the degradation of IgG and thus may be a promising therapeutic agent for IMNM.MethodsAll three patients ...
Qiqi Peng   +5 more
doaj   +1 more source

Effect of FcRn antagonism on protective antibodies and to vaccines in IgG-mediated autoimmune diseases pemphigus and generalised myasthenia gravis

open access: yesAutoimmunity, 2022
Antagonism of the neonatal Fc receptor (FcRn) by efgartigimod has been studied in several autoimmune diseases mediated by immunoglobulin G (IgG) as a therapeutic approach to remove pathogenic IgGs.
Jeffrey T. Guptill   +7 more
doaj   +1 more source

Efgartigimod: a breakthrough medicine for myasthenia gravis

open access: yesInternational Journal of Surgery: Global Health, 2022
Myasthenia gravis (MG) is an autoimmune disease of the neuromuscular junction origin that causes persistent fatigue and weakening of voluntary muscles. MG is the most prevalent neuromuscular junction disorder, with an estimated 150–200 new cases per million individuals per year.
Omer Ahmed Shaikh   +5 more
openaire   +1 more source

Efgartigimod following plasma exchange in the treatment of subjects with generalised myasthenia gravis: study protocol for a multicentre, three-arm, open-label study

open access: yesBMJ Neurology Open
Introduction Myasthenia gravis (MG), an IgG-mediated autoimmune disorder targeting neuromuscular junctions, shows refractory in 12–20% of generalised MG (gMG) patients despite immunotherapies.
Lu Zhang   +14 more
doaj   +1 more source

Fc-Engineered Therapeutic Antibodies: Recent Advances and Future Directions. [PDF]

open access: yes, 2023
Monoclonal therapeutic antibodies have revolutionized the treatment of cancer and other diseases. Fc engineering aims to enhance the effector functions or half-life of therapeutic antibodies by modifying their Fc regions.
Abdeldaim, Dalia T   +1 more
core   +1 more source

Efficacy and Safety of Subcutaneous Efgartigimod PH20 in Adults With Primary Immune Thrombocytopenia (ADVANCE SC): A Multicenter, Randomized, Double‐Blinded, Placebo‐Controlled, Phase 3 Trial

open access: yesAmerican Journal of Hematology, EarlyView.
ABSTRACT Primary autoimmune thrombocytopenia (ITP) is characterized by thrombocytopenia, bleeding, and reduced health‐related quality of life. In the Phase 3 ADVANCE IV study, intravenous efgartigimod induced significant platelet count responses versus placebo in patients with chronic ITP. ADVANCE SC, a Phase 3, multicenter, randomized, double‐blinded,
Nichola Cooper   +546 more
wiley   +1 more source

A pathophysiological and mechanistic review of chronic inflammatory demyelinating polyradiculoneuropathy therapy [PDF]

open access: yes
Chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) is an immune-mediated disease of the peripheral nerves characterized by proximal and distal muscle weakness and sensory abnormalities.
Caballero-Ávila, Marta   +5 more
core   +1 more source

Challenges managing myasthenia gravis: an international perspective [PDF]

open access: yes, 2023
There have been increasing breakthroughs in the diagnosis and treatment of myasthenia gravis over the past decades. However, most published research in myasthenia is conducted in developed regions, such as the US, Canada and Europe.
Alzahmi, Fatmah   +5 more
core   +2 more sources

Digital Phenotyping and Lifestyle Intervention in Patients With Myasthenia Gravis (DIG‐MG): A Randomized Controlled Trial of Feasibility, Adherence, and Effects on Fatigue

open access: yesMuscle &Nerve, EarlyView.
ABSTRACT Introduction/Aims Physical activity and sleep influence fatigue in myasthenia gravis (MG), and digital health technologies (DHT) enable objective monitoring of these behaviors in daily life. Using this approach, we evaluated whether a lifestyle intervention targeting physical activity or sleep hygiene could reduce fatigue in MG.
Maja Norling   +9 more
wiley   +1 more source

Home - About - Disclaimer - Privacy